TherapeuticsMD (TXMD) Income from Continuing Operations (2010 - 2026)
TherapeuticsMD (TXMD) posted Income from Continuing Operations of 103000.0 for Q1 2026, up 117.76% on a QoQ basis from 580000.0 in Q4 2025, and up 116.19% year-over-year from 47642.18 in Q1 2025.
TherapeuticsMD (TXMD) Income from Continuing Operations (2010 - 2026) Analysis & Trends
TherapeuticsMD's Income from Continuing Operations history runs 17 years deep, the most recent figure standing at 103000.0 for Q1 2026.
- Quarterly Income from Continuing Operations rose 116.19% year-over-year to 103000.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was 118000.0 (up 105.44% YoY) and the FY2025 annual result came in at 653000.0, up 71.76% from the prior year.
- Income from Continuing Operations was 103000.0 for Q1 2026 at TherapeuticsMD, up from 580000.0 in the prior quarter.
- Across five years, Income from Continuing Operations topped out at 48453000.0 in Q4 2022 and bottomed at 17875000.0 in Q1 2022.
- A 5-year average of 575235.29 and a median of 809000.0 in 2024 frame the typical range for Income from Continuing Operations.
- Peak annual rise in Income from Continuing Operations reached 151.9% in 2025, while the deepest fall reached 798.8% in 2025.
- TherapeuticsMD's Income from Continuing Operations stood at 48453000.0 in 2022, then slumped by 103.27% to 1584000.0 in 2023, then jumped by 105.24% to 83000.0 in 2024, then plunged by 798.8% to 580000.0 in 2025, then jumped by 117.76% to 103000.0 in 2026.
- Business Quant data shows TXMD's Income from Continuing Operations at 103000.0 in Q1 2026, 580000.0 in Q4 2025, and 50000.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Income (Continuing) (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 87.22 Bn | 85.35 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 39.60 Bn | 35.87 Bn | 1.97 Bn | 370.00 Mn |
| 3 | Zoetis | 31.46 Bn | 29.52 Bn | 1.62 Bn | 601.00 Mn |
| 4 | Takeda Pharmaceutical | 26.49 Bn | 22.44 Bn | 4.39 Bn | -3.58 Bn |
| 5 | United Therapeutics | 23.03 Bn | 20.88 Bn | 648.10 Mn | 274.90 Mn |
| 6 | Universe Pharmaceuticals | 23.03 Bn | -10.56 Bn | - | - |
| 7 | Viatris | 20.90 Bn | 19.09 Bn | 1.16 Bn | 176.40 Mn |
| 8 | Neurocrine Biosciences | 17.50 Bn | 16.19 Bn | 800.70 Mn | 197.90 Mn |
| 9 | Elanco Animal Health | 12.33 Bn | 11.91 Bn | 785.00 Mn | 57.00 Mn |
| 10 | TherapeuticsMD | 280,159.99 | -8.14 Mn | - | 103,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 103,000.00 |
| Dec 31, 2025 | -580,000.00 |
| Sep 30, 2025 | 50,000.00 |
| Jun 30, 2025 | 545,000.00 |
| Mar 31, 2025 | -636,000.00 |
| Dec 31, 2024 | 83,000.00 |
| Sep 30, 2024 | -567,000.00 |
| Jun 30, 2024 | -1.05 Mn |
| Mar 31, 2024 | -809,000.00 |
| Dec 31, 2023 | -1.58 Mn |
| Sep 30, 2023 | -1.43 Mn |
| Jun 30, 2023 | -2.41 Mn |
| Mar 31, 2023 | -2.31 Mn |
| Dec 31, 2022 | 48.45 Mn |
| Sep 30, 2022 | -14.33 Mn |
| Jun 30, 2022 | -15.42 Mn |
| Mar 31, 2022 | -17.88 Mn |
| Dec 31, 2021 | 50.15 Mn |
| Sep 30, 2021 | -47.42 Mn |
| Jun 30, 2021 | -42.65 Mn |